Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Etentamig (ABBV-383) in light chain amyloidosis
2023-503429-20-00Phase 2Authorised
- Sponsor
- AbbVie Inc.
- Start
- Jul 2024
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 6
01
Overview
Phase 2 trial of etentamig in light-chain amyloidosis, sponsored by AbbVie Inc. Planned start Jul 2024; status: authorised.
02
Drugs
etentamig
03
Conditions
light-chain amyloidosis
Beyond the preview
Go deeper on 2023-503429-20-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-503429-20-00.